Proton-pump inhibitors and birth defects - Some reassurance, but more needed

New England Journal of Medicine

Volumn 363, Issue 22, 2010, Pages 2161-2163

  Mitchell, Allen A ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; BIRTH DEFECT; DENMARK; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TERATOGENICITY; UNITED STATES;

EID: 78649429337     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1009631     Document Type: Editorial

References (7)

1. Mitchell AA. Studies of drug-induced birth defects. In: Strom BL. Pharmacoepidemiology. 4th ed. Chichester, England: John Wiley, 2005:501-14.
2. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010;363:2114-23.
3. Diav-Citrin O, Arnon J, Schechtman S, et al. The safety of proton pump inhibitors in pregnancy: a muticentre prospective controlled study. Aliment Pharmacol Ther 2005;21:269-75.
4. Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541-5.
5. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38:90-6.
6. Torfs CP, Lam PK, Schaffer DM, Brand RJ. Association between mothers' nutrient intake and their offspring's risk of gastroschisis. Teratology 1998;58:241-50.
7. Carmichael SL, Rasmussen SA, Lammer EJ, Ma C, Shaw GM. Craniosynostosis and nutrient intake during pregnancy. Birth Defects Res A Clin Mol Teratol 2010 September 14 (Epub ahead of print).